Aegerion Pharmaceuticals, Inc. (AEGR) Tops Q1 EPS by 7c

April 30, 2013 7:34 AM EDT Send to a Friend
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reported Q1 EPS of ($0.64), $0.07 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $570 thousand.

Highlights

  • Aegerion has more than 185 U.S. commercial and global named patient prescriptions for JUXTAPID written, and 75 patients are currently on JUXTAPID therapy. Re-orders for patients are on track and dropouts to date have been minimal.
  • A significant foundation of REMS-trained physicians is established and growing.
  • The company participated in a Scientific Advisory Group meeting at the European Medicines Agency (EMA) on April 9th.

    2013 Financial Guidance

    Aegerion continues to expect total operating expenses, excluding stock-based compensation expense, to be between $75 and $85 million in 2013. The Company expects GAAP operating expenses in 2013, including stock-based compensation, to be between $95 and $105 million. Aegerion also expects global net product sales of $15 million to $25 million for FY 2013 and 250 to 300 patients on JUXTAPID therapy globally by year-end 2013.

    For earnings history and earnings-related data on Aegerion Pharmaceuticals, Inc. (AEGR) click here.


  • Serious News for Serious Traders! Try StreetInsider.com Premium Free!

    You May Also Be Interested In





    Related Categories

    Earnings, Guidance

    Related Entities

    Earnings

    Add Your Comment